Clinical Trial Update: Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

View source ↗

Summary

A clinical trial sponsored by Proteocyte Diagnostics Inc. is evaluating an S100A7 immunohistochemistry signature-based assay for early prediction of oral cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cancer

Drugs mentioned

• S100A7 IHC signature-based assay

Snippet

Sponsor: Proteocyte Diagnostics Inc. | Conditions: Oral Neoplasm | Status: RECRUITING